Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Edit custom filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1966 1
1969 1
1974 1
1975 1
1977 2
1978 2
1980 1
1981 1
1989 4
1990 1
1991 2
1992 1
1994 6
1995 1
1996 5
1997 2
1998 3
1999 2
2000 2
2001 3
2002 1
2004 8
2005 7
2006 6
2007 4
2008 4
2009 4
2010 10
2011 9
2012 5
2013 6
2014 7
2015 2
2016 3
2017 4
2019 1
2021 1
2022 1
2026 0

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

112 results

Results by year

Filters applied: . Clear all
Page 1
Reduced cognitive and psychomotor impairment with extended-release oxymorphone versus controlled-release oxycodone.
Schoedel KA, McMorn S, Chakraborty B, Zerbe K, Sellers EM. Schoedel KA, et al. Pain Physician. 2010 Nov-Dec;13(6):561-73. Pain Physician. 2010. PMID: 21102969 Free article. Clinical Trial.
OBJECTIVE: To compare cognitive and psychomotor effects of oxymorphone extended release (OM-ER) versus oxycodone controlled release (OC-CR). STUDY DESIGN: Randomized, double-blind, 5-way crossover SETTING: Single inpatient research unit METHODS: Nondependent recreational o …
OBJECTIVE: To compare cognitive and psychomotor effects of oxymorphone extended release (OM-ER) versus oxycodone controlled release ( …
Efficacy of oxymorphone extended release in postsurgical pain: a randomized clinical trial in knee arthroplasty.
Ahdieh H, Ma T, Babul N, Lee D. Ahdieh H, et al. J Clin Pharmacol. 2004 Jul;44(7):767-76. doi: 10.1177/0091270004266487. J Clin Pharmacol. 2004. PMID: 15199081 Clinical Trial.
Patients with moderate or severe pain following knee arthroplasty and washout from standard patient-controlled analgesia (PCA) were randomized to receive 20 mg of an extended-release (ER) oxymorphone formulation (n = 65) or placebo (n = 61) q12h for 1 day. Oxymorphone …
Patients with moderate or severe pain following knee arthroplasty and washout from standard patient-controlled analgesia (PCA) were randomiz …
Relative potency of intravenous oxymorphone compared to other opioid agonists in humans - pilot study outcomes.
Babalonis S, Comer SD, Jones JD, Nuzzo P, Lofwall MR, Manubay J, Hatton KW, Whittington RA, Walsh SL. Babalonis S, et al. Psychopharmacology (Berl). 2021 Sep;238(9):2503-2514. doi: 10.1007/s00213-021-05872-1. Epub 2021 Jun 1. Psychopharmacology (Berl). 2021. PMID: 34106317 Free PMC article. Clinical Trial.

Across abuse-related subjective outcomes, oxymorphone was 2.3-2.8-fold more potent than hydromorphone and 12.5-14-fold more potent than oxycodone (p < 0.05). CONCLUSIONS: Despite the relatively small sample size, this pilot study detected robust oxymorphone effec

…
Across abuse-related subjective outcomes, oxymorphone was 2.3-2.8-fold more potent than hydromorphone and 12.5-14-fold more potent th …
Bioequivalence of oxymorphone extended release and crush-resistant oxymorphone extended release.
Benedek IH, Jobes J, Xiang Q, Fiske WD. Benedek IH, et al. Drug Des Devel Ther. 2011;5:455-63. doi: 10.2147/DDDT.S24372. Epub 2011 Nov 23. Drug Des Devel Ther. 2011. PMID: 22162639 Free PMC article. Clinical Trial.
The purpose of this study was to evaluate the bioequivalence of oxymorphone extended-release (Oxy-ER) and a crush-resistant formulation of oxymorphone extended-release (Oxy-CRF). ...Subjects administered 40 mg doses also received naltrexone. The primary endpoint was …
The purpose of this study was to evaluate the bioequivalence of oxymorphone extended-release (Oxy-ER) and a crush-resistant formulati …
Genetic polymorphisms and drug interactions modulating CYP2D6 and CYP3A activities have a major effect on oxycodone analgesic efficacy and safety.
Samer CF, Daali Y, Wagner M, Hopfgartner G, Eap CB, Rebsamen MC, Rossier MF, Hochstrasser D, Dayer P, Desmeules JA. Samer CF, et al. Br J Pharmacol. 2010 Jun;160(4):919-30. doi: 10.1111/j.1476-5381.2010.00709.x. Br J Pharmacol. 2010. PMID: 20590588 Free PMC article. Clinical Trial.
CYP3A4 blockade had a major effect on all pharmacodynamic assessments and SPT increased by 15%. Oxymorphone C(max) was correlated with SPT assessment (rho(S)= 0.7) and the only independent positive predictor of SPT. ...
CYP3A4 blockade had a major effect on all pharmacodynamic assessments and SPT increased by 15%. Oxymorphone C(max) was correlated wit …
Single- and multiple-dose pharmacokinetic and dose-proportionality study of oxymorphone immediate-release tablets.
Adams MP, Ahdieh H. Adams MP, et al. Drugs R D. 2005;6(2):91-9. doi: 10.2165/00126839-200506020-00004. Drugs R D. 2005. PMID: 15777102 Clinical Trial.
INTRODUCTION: Oxymorphone hydrochloride (referred to as oxymorphone), a semisynthetic mu-opioid agonist, is known to produce a more rapid onset of action and greater analgesic potency compared with its parent compound, morphine. Until recently, oxymorphone ha …
INTRODUCTION: Oxymorphone hydrochloride (referred to as oxymorphone), a semisynthetic mu-opioid agonist, is known to produce a …
Maturation of oxycodone pharmacokinetics in neonates and infants: Oxycodone and its metabolites in plasma and urine.
Kokki M, Heikkinen M, Välitalo P, Hautajärvi H, Hokkanen J, Pitkänen H, Sankilampi U, Ranta VP, Kokki H. Kokki M, et al. Br J Clin Pharmacol. 2017 Apr;83(4):791-800. doi: 10.1111/bcp.13164. Epub 2016 Dec 5. Br J Clin Pharmacol. 2017. PMID: 27780305 Free PMC article. Clinical Trial.
Three to seven blood samples were taken from each infant, and plasma concentrations of oxycodone, noroxycodone, oxymorphone, and noroxymorphone were quantified. The unconjugated forms of these compounds were determined in urine collected after up to 24 or 48 h from 25 infa …
Three to seven blood samples were taken from each infant, and plasma concentrations of oxycodone, noroxycodone, oxymorphone, and noro …
Association of Physical Activity With Bioactive Lipids and Cardiovascular Events.
Hoshi RA, Liu Y, Luttmann-Gibson H, Tiwari S, Giulianini F, Andres AM, Watrous JD, Cook NR, Costenbader KH, Okereke OI, Ridker PM, Manson JE, Lee IM, Vinayagamoorthy M, Cheng S, Copeland T, Jain M, Chasman DI, Demler OV, Mora S. Hoshi RA, et al. Circ Res. 2022 Aug 5;131(4):e84-e99. doi: 10.1161/CIRCRESAHA.122.320952. Epub 2022 Jul 19. Circ Res. 2022. PMID: 35862024 Free PMC article. Clinical Trial.
Annotations were found for 6 of these BALs: 12,13-diHOME, 9,10-diHOME, lysoPC(15:0), oxymorphone-3b-D-glucuronide, cortisone, and oleoyl-glycerol. Genetic analysis within JUPITER-NC showed associations of 32 PA-related BALs with 22 single-nucleotide polymorphisms. ...
Annotations were found for 6 of these BALs: 12,13-diHOME, 9,10-diHOME, lysoPC(15:0), oxymorphone-3b-D-glucuronide, cortisone, and ole …
Cardiorespiratory effects of four opioid-tranquilizer combinations in dogs.
Jacobson JD, McGrath CJ, Smith EP. Jacobson JD, et al. Vet Surg. 1994 Jul-Aug;23(4):299-306. doi: 10.1111/j.1532-950x.1994.tb00488.x. Vet Surg. 1994. PMID: 8091634 Clinical Trial.
Buprenorphine (BUP; 0.01 mg/kg IV) or oxymorphone (OXY; 0.1 mg/kg IV) was followed in 10.4 +/- 1.3 minutes by midazolam (MID; 0.3 mg/kg IV) or acepromazine (ACE; 0.05 mg/kg IV). ...
Buprenorphine (BUP; 0.01 mg/kg IV) or oxymorphone (OXY; 0.1 mg/kg IV) was followed in 10.4 +/- 1.3 minutes by midazolam (MID; 0.3 mg/ …
112 results